MEDVi vs Ro vs PlexusDx (2026)

Last reviewed: May 12, 2026 Last updated: May 12, 2026

Written by: Jay Hastings , CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance. His work has included scaling healthcare startups, leading CLIA lab integrations, and helping expand consumer access to precision health tools.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — your resource for evidence-based guidance on GLP-1 therapies, weight management protocols, and the genetic variables that shape every metabolic decision. Browse all Peptides & GLP-1 education

If you’re cross-shopping MEDVi and Ro for cash-pay GLP-1 weight loss, the headline numbers are misleading. MEDVi advertises $179 for month one then $299/month with medication included; Ro advertises $149/month for the membership before you pay anything for the medication itself. The two prices look comparable on a landing page; in your bank account, they aren’t. This article walks the actual cost math, the medication-source difference (compounded vs FDA-approved branded), the safety considerations on each side, and where PlexusDx Semaglutide Injection, Tirzepatide Injection, and Microdose GLP-1 Protocol sit relative to both — because the choice between MEDVi, Ro, and PlexusDx isn’t really about which company is “better.” It’s about medication source, oversight model, total annualized cost, and whether genetics inform your dose before week one.

MEDVi vs Ro vs PlexusDx — quick decision frame

Three pricing models cover the cash-pay GLP-1 market. MEDVi is an all-inclusive compounded-medication platform: $179 for month one then $299/month covers the clinician visit, the compounded semaglutide or tirzepatide vials, supplies, and shipping in one bill. Ro is a membership-plus-medication model: $149/month buys the clinical visit, coaching, and prescription routing; the GLP-1 medication itself is dispensed separately — typically Wegovy or Zepbound at the FDA-approved branded list price (often $1,000–$1,350/month before insurance), or compounded options at varying tiers. PlexusDx Weight Management Protocols use compounded semaglutide and tirzepatide from licensed U.S. compounding pharmacies — Semaglutide Injection at $149/mo, Tirzepatide Injection at $249/mo, Microdose GLP-1 Protocol at $129/mo flat, and GLP-Squared dual-compound at $249/mo — paired with the optional Precision Peptide Genetic Test ($298 standalone or $99 as an add-on after your first month) so dosing decisions are anchored to the patient’s GIPR, FTO, MC4R, and TCF7L2 variants rather than starting from population averages. All three pricing models are cash-pay; PlexusDx adds no membership fee.

The real annual cost: MEDVi vs Ro vs PlexusDx

For a cash-pay patient with no insurance coverage for weight-loss drugs, MEDVi’s all-inclusive pricing produces a total of roughly $3,468/year on the standard semaglutide plan ($179 month one + $299 × 11). Ro’s $149/month membership plus the medication runs in a wide range depending on what gets dispensed: roughly $3,428–$5,828/year for compounded options at varying doses, and substantially higher if branded Wegovy or Zepbound are billed cash-pay. PlexusDx Weight Management Protocols range from $1,548/year on the Microdose GLP-1 Protocol ($129/mo flat) to $2,148–$2,748/year on Semaglutide Injection ($149/mo), $2,748–$3,708/year on Tirzepatide Injection ($249/mo), or $2,148–$3,900/year on GLP-Squared ($249/mo). Add $99 for the Precision Peptide Genetic Test as an add-on after month one and the genetic-baseline-included totals stay below MEDVi on the lower-cost protocols. If your insurance reliably covers Wegovy or Zepbound at a low copay, Ro’s branded-pharmacy route can still win on net cost. If your insurance doesn’t cover GLP-1s for weight loss — most commercial plans as of April 2026 — PlexusDx’s protocol pricing is meaningfully below MEDVi at the entry tier and competitive at the higher tiers.

Compounded vs FDA-approved branded — what each platform dispenses

This is the substantive medication difference and it’s worth understanding before signing up for any of the three. MEDVi’s core all-inclusive plans dispense compounded semaglutide and tirzepatide — formulations prepared by a licensed compounding pharmacy under U.S. compounding regulations. Compounded semaglutide and tirzepatide are not FDA-approved finished drug products; they are pharmacy-prepared versions of the same active ingredients found in Wegovy, Ozempic, Mounjaro, and Zepbound. Ro’s pathways include FDA-approved branded GLP-1 medications — Wegovy (semaglutide) and Zepbound (tirzepatide), the same products that ran the SUSTAIN, STEP, and SURMOUNT trials — alongside compounded options at other tiers. PlexusDx Weight Management Protocols use compounded semaglutide and tirzepatide like MEDVi, but offer four delivery formats — weekly injection, daily oral tablet, microdose troche/capsule/lozenge/sublingual, and dual-compound stacks — at protocol-specific dose ranges, paired with a genetic baseline. The compounded vs branded choice is not about effectiveness of the active ingredient — it’s about FDA approval status of the finished product, supply consistency, and which regulatory framework governs your medication.

Safety, side effects, and clinical oversight

All three programs prescribe medications in the GLP-1 receptor agonist class, plus tirzepatide’s GIP/GLP-1 dual-agonist mechanism. The labeled side-effect profile is well-characterized: nausea, vomiting, diarrhea, constipation, abdominal pain, and headache are common; pancreatitis, gallbladder disease, and acute kidney injury are less common but documented. The boxed warning for thyroid C-cell tumors applies to BOTH semaglutide and tirzepatide based on rodent studies — that warning travels with the active ingredient regardless of whether you receive a branded or compounded version. The clinical-oversight question differs by platform. Ro routes prescriptions through licensed providers and partner pharmacies; the FDA-approved label and post-market surveillance apply directly when branded products are dispensed. MEDVi routes through a licensed clinician and a compounding pharmacy partner. PlexusDx uses licensed U.S. compounding pharmacies and a clinical team that can review the patient’s genetic test before titration when the test is included — a stratification step neither MEDVi nor Ro performs. PlexusDx is cash-pay across all 50 states; five states require a scheduled live consultation rather than async intake.

How each program actually works (intake, approval, shipping)

MEDVi runs an asynchronous intake: complete a medical questionnaire, a clinician reviews the case, and most patients are approved within 24–48 hours, with compounded medication shipped from a partner pharmacy shortly after. Ro’s flow is similar on the cash-pay side — intake form, provider review, prescription routed to a partner pharmacy — with insurance routes adding 1–3+ weeks for prior authorization processing. PlexusDx Weight Management Protocols also run async in 45 of 50 states (live consult required in AR, DC, ID, KS, LA), with the prescription routed to a licensed compounding pharmacy and shipped to your door. Where PlexusDx differs is the option to bolt on the Precision Peptide Genetic Test at $99 after month one — saliva collection at home, results delivered through the Peptide Pathways Report in the Results Portal, and the prescribing clinician uses those results to inform titration choices on subsequent refills.

Why genetics matter before you choose

GLP-1 response varies meaningfully across patients. Variants in GIPR (the GIP receptor relevant to tirzepatide’s dual mechanism), FTO (appetite regulation), MC4R (satiety signaling), and TCF7L2 (insulin response) are associated with measurably different response patterns to semaglutide and tirzepatide. The Precision Peptide Genetic Test maps 48 genes and 57 variants across 14 health pathways — including 34 weight-management insights and the GIPR rs1800437 variant linked to differential GLP-1 response — so the prescribing clinician knows whether a faster-than-typical titration, a slower one, or a tirzepatide-first approach is more likely to fit your biology before week one. Neither MEDVi nor Ro performs this step — both start from a population-average titration schedule and adjust based on subjective tolerability over the first 8–12 weeks. PlexusDx anchors that same conversation to a measurable genetic baseline, available standalone for $298 or as a $99 add-on after your first month on any protocol.

Reviews, refunds, and the fine print

MEDVi carries a higher Trustpilot average than Ro at the time of source publication (4.4 vs 3.8), with a much larger review volume on MEDVi’s side. Both platforms operate month-to-month with no long-term contract. Refund policies differ: MEDVi’s public refund policy refunds only when a patient is medically disqualified after payment — ordinary cancellation or dissatisfaction does not trigger a refund; Ro does not advertise a money-back guarantee. PlexusDx is cash-pay with no membership fee, no long-term contract, and pricing that is identical from month one onward (no “intro month” that resets to a higher rate later). Always read the current refund and cancellation policy on whichever platform you choose — policies change.

Which one fits — a four-question frame

Question 1: Does your insurance reliably cover Wegovy or Zepbound at a low copay? If yes, Ro’s branded-pharmacy route is likely cheapest on a net basis. Question 2: Are you cash-pay with no GLP-1 coverage and price is the dominant factor? Compare MEDVi’s $3,468/year all-inclusive to PlexusDx Microdose GLP-1 Protocol at $1,548/year or PlexusDx Semaglutide Injection at $2,148–$2,748/year. Question 3: Do you specifically want the FDA-approved branded finished product? Ro is the only option of the three that consistently dispenses Wegovy or Zepbound directly. Question 4: Do you want a genetic baseline informing dose and titration before the first injection? PlexusDx is the only option in this comparison that includes the Precision Peptide Genetic Test as part of the protocol pathway.

Frequently asked questions

Is MEDVi cheaper than Ro?

For cash-pay patients without insurance, MEDVi is typically lower than Ro on a total-of-payments basis — MEDVi’s ~$3,468 first-year semaglutide total bundles the medication into the monthly fee, while Ro’s $149/month membership plus separate medication can run $3,428–$5,828/year on compounded options and substantially higher on cash-pay branded. If your commercial plan covers Wegovy or Zepbound at a low copay, Ro can be cheapest overall. PlexusDx Microdose GLP-1 Protocol at $129/mo flat ($1,548/year) is the lowest-cost option of the three when it’s clinically appropriate.

Does MEDVi prescribe the same medication as Ro?

Not exactly. MEDVi’s core all-inclusive plans use compounded semaglutide and tirzepatide — not FDA-approved finished products. Ro’s pathways include FDA-approved branded Wegovy and Zepbound from Novo Nordisk and Eli Lilly, alongside compounded options at other tiers. Compounded medications are not FDA-approved finished drugs and are not interchangeable with the branded versions, even when they share the same active ingredient.

Can I switch between MEDVi, Ro, and PlexusDx?

Yes — all three are month-to-month with no long-term contracts. Cancel before your next billing date on the platform you’re leaving, then enroll on the new one. Each new provider conducts its own medical evaluation; an existing prescription does not carry over. PlexusDx adds no membership fee, so switching to a PlexusDx protocol means you stop paying any platform charge at all and pay only the protocol price.

Are GLP-1 medications safe?

GLP-1 receptor agonists are among the most extensively studied weight-loss medications. Common side effects (nausea, constipation, diarrhea) usually improve over the first 8–12 weeks. Less common but serious risks include pancreatitis, gallbladder disease, and acute kidney injury. The boxed warning for thyroid C-cell tumors applies to both semaglutide and tirzepatide based on rodent studies — discuss your personal and family history with a clinician before starting any GLP-1.

Does MEDVi or Ro offer a money-back guarantee?

MEDVi’s public refund policy refunds only when a patient is medically disqualified after payment — ordinary cancellation, dissatisfaction, or stopping voluntarily does not qualify. Ro does not advertise a money-back guarantee. Always review the current refund and cancellation policy on the platform you choose; policies change without notice.

What if I’m afraid of needles?

All three platforms offer needle-free options. MEDVi offers compounded sublingual tablets. Ro offers the Wegovy oral tablet (FDA-approved daily oral semaglutide) on its branded path. PlexusDx offers the Microdose GLP-1 Protocol at $129/mo flat with capsule, troche, lozenge, and sublingual delivery variants, plus Semaglutide Oral from $249/mo and Tirzepatide Oral from $229/mo for daily-tablet patients.

How does PlexusDx differ from MEDVi and Ro?

PlexusDx is cash-pay, no membership, all 50 states (five require a live consult), with six prescription protocols spanning microdose, oral, weekly injection, and dual-compound mechanisms from $129/mo to $325/mo. The optional Precision Peptide Genetic Test ($298 standalone or $99 add-on after month one) gives the prescribing clinician a genetic baseline on GIPR, FTO, MC4R, and TCF7L2 before titration — a step neither MEDVi nor Ro performs.

MEDVi vs Ro vs PlexusDx (2026): Real Cost, Compounded vs Branded, Genetic Baseline | PlexusDx